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Abstract
 
CD40 ligand (CD154) expression on activated T cells can be separated into an early TCR-
dependent phase, which occurs between 0 and 24 h after activation, and a later extended phase,
which occurs after 24 h and is reciprocally regulated by the cytokines IL-4 and IL-12. IL-4 re-
presses, whereas IL-12 sustains CD154 expression. Consistent with this, Th1, but not Th2,
cells express CD154 for extended periods. Differences in the duration of CD154 expression
have important biological consequences because sustained, but not transient, expression of
CD154 on activated T cells can prevent B cell terminal differentiation. Thus, the differential
ability of Th cells to sustain CD154 expression is an important part of their helper function and
should influence the activities of other CD40-expressing cell types.
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Introduction
 
CD40 is constitutively expressed on B cells and other APCs
(1) and is essential for the success of both cellular and hu-
moral immune responses (2–4). In humoral immune re-
sponses, CD40 signaling induces B cell activation and facil-
itates T-dependent B cell proliferation (5–7), germinal
center formation (3, 8, 9), and immunoglobulin isotype-
switching (10–12). Several reports also suggest that CD40
signaling directly induces B cell terminal differentiation and
antibody secretion (13–15), however, we and others
showed that CD40 signaling actively prevents B cell termi-
nal differentiation and antibody secretion (16–20). Interest-
ingly, the major differences between the studies showing
that CD40 signaling promotes antibody secretion and those
showing that CD40 signaling inhibits antibody secretion
are in the reagents used to trigger CD40 and the duration
of the CD40 signal. This indicates that there are both qual-
itative and quantitative aspects of CD40 engagement that
can dictate the biological outcome of CD40 signals in B
lymphocytes. Since CD40 signaling in vivo is controlled by
the availability of its ligand, CD154, the factors that regu-
late the level and duration of CD154 expression on the sur-
face of T helper cells should therefore influence B cell differ-
entiation and antibody secretion.
The initial studies of CD154 expression were performed
with T cell clones (21–24) and suggested that CD154 ex-
pression is rapidly, but transiently, induced after T cell acti-
vation (21–23). One explanation for the transient nature of
CD154 expression on APC-activated T cells is that CD154
is internalized upon encounter with CD40-expressing
APCs (25). Consistent with the model of endosomal recy-
cling, some memory T cells have preformed CD154 that
can be rapidly expressed on the cell surface after TCR acti-
vation (26). Thus, T cells seem to have several mechanisms
to ensure the rapid, yet transient, expression of CD154 on
the cell surface. Although some cytokines, such as IFN-
 
 
 
and TGF
 
 
 
, appear to reduce CD154 expression on some T
cell clones (23), cytokines in general are not thought to
regulate CD154 expression. Furthermore, because CD154
is rapidly expressed by both Th1 and Th2 cell lines within
hours of stimulation (22, 23), differential CD154 expression
is not thought to be a feature of Th cell polarization. Sub-
sequent studies demonstrated that the rapid induction of
CD154 expression on naive T cells occurs primarily
through TCR stimulation, and although interactions be-
tween B7 and CD28 appear to augment CD154 expression
(27–29), these interactions act by facilitating a more avid
TCR engagement rather than directly inducing CD154
expression (30, 31).
In contrast to the prevailing opinion that CD154 ex-
pression is only transiently expressed for a few hours after T
cell activation, there are scattered reports indicating that ac-
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tivated T cells can express CD154 for as long as 4 d (27, 29,
32). For example, the cytokines IL-2 and IL-15 appear to
reinduce the expression of CD154 on effector T cells in the
absence of TCR signaling (33). Additionally, IL-12 is re-
ported to sustain CD154 expression on anti-CD3–activated
T cells for up to 3 d (32). Furthermore, there are several re-
ports of extended CD154 expression on T cells activated
with anti-CD3, with or without anti-CD28 costimulation
(27, 28, 30, 34, 35). Unfortunately, these studies are diffi-
cult to reconcile with those suggesting that CD154 is only
transiently expressed on activated T cells, due to differences
in the source of the responding T cells, methods of stimula-
tion, and the times at which CD154 expression was exam-
ined. Since the kinetics and duration of CD154 expression
likely control many APC effector functions, it is critical to
better define the mechanisms that control expression of
CD154 on antigen-activated T cells. Therefore, we set out
to methodically determine the factors that control extended
CD154 expression on activated T cells and to test whether
sustained expression of CD154 can influence the antibody-
secreting effector function of activated B cells.
 
Materials and Methods
 
Animals.
 
B10.BR as well as AND TCR transgenic mice (36)
on the B10.BR, C57BL/6, or C57BL/6–IL-4KO backgrounds
were bred in the Trudeau Institute Animal Breeding Facility.
B10.A mice were purchased from Jackson ImmunoResearch
Laboratories. All procedures involving animals were approved by
the Trudeau Institute Institutional Animal Care and Use Com-
mittee and were conducted according to the principles outlined
by the National Research Council.
 
Cell Isolation.
 
CD4
 
 
 
 T cells were purified from AND mice
by positive selection. In brief, single cell suspensions were ob-
tained from the spleens and LN of 4–6-wk-old mice and were
incubated with FcR-blocking antibody (2.4G2) at 1 
 
 
 
g/10
 
7
 
 cells
for 15 min on ice. Anti-CD4 magnetic beads (Miltenyi Biotec)
were added at 25 
 
 
 
l/10
 
8
 
 total cells in 100 
 
 
 
l final volume for an
additional 15 min on ice. Cells were washed, filtered, and passed
over a type LS
 
 
 
 magnetic column (Miltenyi Biotec). After wash-
ing, the magnetically bound cells were eluted from the column
with the supplied plunger. This procedure routinely resulted in
95–98% pure CD4
 
 
 
 T cells, of which 
 
 
 
90% expressed the TCR
transgene. B cells were positively selected with anti-B220 beads
using similar methods. The B cell lymphoma cell line, CH12,
was maintained by weekly passage in B10.A mice as described
(20, 37). Briefly, 10
 
6
 
 CH12 cells were injected into the peritoneal
cavity of B10.A mice and 
 
 
 
5 
 
 
 
 10
 
8
 
 CH12 cells were recovered
7 d later by peritoneal lavage. The purity of the recovered cells
was typically 
 
 
 
95% and the cells were used without any addi-
tional purification.
(4-hydroxy-3-nitrophenyl)acetyl (NP)
 
*
 
-specific B cells were
obtained from the spleens of B10.BR mice immunized 7 d previ-
ously with a combination of 50 
 
 
 
g NP-ovalbumin and 50 
 
 
 
g
NP-pigeon cytochrome 
 
c
 
 adsorbed to alum. Splenocytes were
stained with biotinylated anti-
 
 
 
, NP-allophycocyanin, and anti-
CD138. 
 
 
 
-Expressing cells were positively selected using strepta-
 
vidin-coated magnetic beads (25 
 
 
 
l/10
 
8
 
 total cells in 100 
 
 
 
l final
volume) to bind cells to a type C magnetic column (Miltenyi
Biotec). The selected cells were sorted for NP binding and the
absence of CD138. The resulting cells were 
 
 
 
95% pure.
 
Generation of Polarized Effector or Memory T Cells.
 
AND
CD4
 
 
 
 effector cells were generated as previously described (38).
In brief, purified CD4
 
 
 
 T cells from AND TCR Tg mice were
cultured at 2 
 
 
 
 10
 
5
 
/ml with 5 
 
 
 
M PCCF and mitomycin
C–treated DCEK-ICAM cells in the presence of polarizing cyto-
kines and antibodies for 4 d. Th1 polarizing conditions included
100 ng/ml IL-2, 2 ng/ml IL-12, and 10 
 
 
 
g/ml anti–IL-4
(11B11). Th2 polarizing conditions included 100 ng/ml IL-2, 15
ng/ml IL-4, and 10 
 
 
 
g/ml anti–IFN-
 
 
 
 (XMG1.2). Polarized ef-
fector cells were used after 4 d of culture. To generate memory T
cells, day 4 effectors were adoptively transferred into B10.BR
mice that had been previously thymectomized, irradiated, and re-
constituted with 2 
 
 
 
 10
 
6
 
 syngeneic T-depleted bone marrow
(38, 39). Memory CD4
 
 
 
 T cells were recovered 5–10 wk after
transfer.
 
Cell Culture and T and B Cell Activation.
 
Cells were cultured
in RPMI 1640 supplemented with vitamins, nonessential amino
acid, glucose, sodium pyruvate, HEPES, penicillin, streptomycin,
glutamine, and 10% FBS from GIBCO BRL. T cells were cul-
tured in 48-well plates at 10
 
6
 
 cells/ml and were stimulated using
plate bound anti-CD3
 
 
 
 at 10 
 
 
 
g/ml. In other experiments, AND
T cells (10
 
6 
 
cells/ml) were cocultured with CH12 cells (10
 
5
 
 cells/
ml) in 96-well round-bottom plates with combinations of cyto-
kines and antibodies as indicated in the figures and figure legends.
In some experiments, activated B cells were generated by stimu-
lating purified splenic B cells with rabbit Fab
 
 
 
2 anti-IgM at 10
 
 
 
g/ml and the supernatant of BAFF-transfected L cells.
 
Cytokines, Mitogens, and Antibodies Used in Culture.
 
Purified,
endotoxin-free CD154-blocking antibody, MR-1 (40), was ob-
tained from Bio Express. IL-4–blocking antibody (11B11) and
IFN-
 
 
 
–blocking antibody (XMG1.2) were purified from cul-
ture supernatant. Recombinant IL-2, IL-4, and IL-10 were
provided by Dr. Frances Lund, Trudeau Institute, Saranac
Lake,  NY. IFN-
 
 
 
 was obtained from culture supernatant of
X63.Ag8–653 cells transfected with IFN-
 
 
 
 cDNA. IL-12 was
provided by Dr. Stanley Wolf, Genetics Institute, Cambridge,
MA. Other reagents purchased were as follows: LPS 
 
Escherichia
coli
 
 O55:B5 (Difco), IL-5 (Sigma-Aldrich), IL-6 (Genzyme),
and IL-13 (BD Biosciences).
 
Analysis of CD154 Expression.
 
CD154 expression was assayed
by staining cultured cells with biotinylated anti-CD154 (MR-1)
followed by APC-streptavidin. Control staining for CD154 was
achieved by adding excess unlabeled MR-1 to the standard stain-
ing procedure. Anti–Thy-1 was used to distinguish T cells from
CH12 cells in cultures containing both cell types. All staining
procedures were performed in the presence of FcR-blocking an-
tibody (2.4G2). Flow cytometry was performed using a dual laser
FACSCalibur™ (Becton Dickinson). The data were analyzed
with FlowJo software (TreeStar).
 
Assay for Antibody Secretion.
 
Cells were harvested from cul-
tures containing both T cells and CH12 cells at 48 or 72 h and
washed twice in PBS. Cells were stained with anti–Thy-1 to de-
termine the relative numbers of T and B cells and equivalent
numbers of B cells were recultured with fresh media and allowed
to secrete antibody for 6 h without further stimulation. Superna-
tants were harvested and assayed for IgM secretion by ELISA. In
brief, plates were coated with goat anti-
 
 
 
,
 
 
 
and IgM in culture su-
pernatants was detected with HRP-labeled goat anti–mouse IgM.
The purified mAb TEPC 183 was used as a standard. NP-specific
 
*
 
Abbreviations used in this paper:
 
 NP, (4-hydroxy-3-nitrophenyl)acetyl;
PCC, pigeon cytochrome 
 
c
 
; PCCF, PCC fragment. 
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antibody was assayed by ELISA by coating plates with NP-BSA
and developing with HRP conjugated anti-IgG.
 
Cytokine Detection Assays.
 
IL-2 was quantitated by measuring
the proliferation of the IL-2–dependent cell line, NK3, in the
presence of the IL-4–blocking antibody 11B11 relative to a re-
combinant IL-2 standard. IL-4 and IFN-
 
 
 
 were quantitated by
ELISA relative to recombinant IL-4 and IFN-
 
 
 
 standards.
 
Results
 
Two Phases of CD154 Expression on Activated Naive T
Cells.
 
To determine the kinetics of CD154 expression af-
ter T cell activation, purified naive CD4
 
 
 
 T cells from
AND TCR transgenic mice were stimulated with plate-
bound anti-CD3 in the absence of APCs. As shown in Fig.
1 A, CD154 expression was rapidly induced on a portion
of the AND T cells after anti-CD3 stimulation. Surpris-
ingly, high levels of CD154 were still observed on the ma-
jority of T cells between 24 and 72 h after stimulation. To
determine whether CD154 was expressed with similar ki-
netics in a more physiological model of T cell activation,
we cultured purified naive AND T cells, which recognize
pigeon cytochrome 
 
c
 
 peptide 88–104 (PCCF) on I-E
 
k
 
,
with the I-E
 
k
 
–expressing B cell lymphoma, CH12, in the
presence or absence of PCCF. As seen in Fig. 1 B, a cog-
nate interaction between AND T cells and PCCF-present-
ing CH12 cells resulted in expression of CD154 on about a
third of the T cells as early as 6 h after activation. In con-
trast to our results using anti-CD3–activated AND T cells,
we found that at 24 h, CD154 was almost undetectable on
the surface of AND T cells stimulated in a cognate interac-
tion. However, by 48 h, a second wave of CD154 expres-
sion was observed on essentially all cells, which then de-
clined by 72 h after stimulation. In experiments not shown,
we demonstrated that the temporary drop in CD154 ex-
pression at 24 h on T cells stimulated in a cognate interac-
tion is due to the internalization of CD154 upon encounter
with CD40 on the APC. This is consistent with previous
results (25).
 
Cytokines Control the Second Phase of CD154 Expression on
Stimulated Naive Cells.
 
To determine whether cytokines
played a role in regulating the first or second phases of
CD154 expression on activated T cells, purified naive
AND T cells were stimulated with CH12 cells and PCCF
in the presence of a variety of cytokines, and the kinetics
of CD154 expression were followed over 72 h. We found
that IL-2, IL-5, IL-6, IL-10, IL-13, and IFN-
 
 
 
 had no ef-
fect on either the levels or kinetics of CD154 expression
(unpublished data). However, both IL-4 and IL-12 influ-
enced the second phase of CD154 in the model of cognate
T–B interaction (Fig. 2 A). Although IL-12 had minimal
effect on the level of CD154 expression on peptide-stimu-
lated T cells at 6 h, IL-4 slightly, but consistently, in-
creased the percentage of cells expressing CD154 at this
time (Fig. 2 A). Similar to what we observed in Fig. 1 B,
there was a dramatic decrease in CD154 expression on T
cells stimulated with peptide-presenting CH12 cells for
24 h, regardless of cytokine addition (Fig. 2 A). In striking
contrast, however, the second phase of CD154 expression
at 48 and 72 h was completely absent on T cells cultured
with IL-4, whereas the second phase of CD154 expression
remained elevated for extended periods on T cells cultured
with IL-12 (Fig. 2 A). Furthermore, the inhibitory effects
of IL-4 were dominant over the effects of IL-12 as T cells
stimulated in the presence of both cytokines expressed
CD154 in a pattern identical to that on T cells stimulated
in the presence of IL-4 alone (Fig. 2 A). Similar results
were seen using OTII transgenic T cells and with normal
T cells (not depicted).
To demonstrate that the cytokines were acting directly
on T cells to influence CD154 expression, rather than on
CH12 cells, purified T cells were stimulated with plate-
bound anti-CD3 (without APCs) in the presence of either
IL-4 or IL-12. As shown in Fig. 2 B, the expression of
CD154 at 6 h on T cells stimulated through CD3 was
somewhat decreased by the addition of IL-4 or IL-12, al-
though in most experiments there was little change. How-
ever, the addition of IL-4 resulted in a strong reduction of
CD154 surface expression at later times in anti-CD3 stimu-
lated cultures (Fig. 2 B). In contrast, the addition of IL-12
resulted in a more robust and prolonged expression of
CD154 at later points after anti-CD3 stimulation (Fig. 2
B). Therefore, we concluded that IL-4 and IL-12 were act-
ing directly on the T cells to influence CD154 expression.
Because the surface expression of CD154 can be regu-
lated by multiple mechanisms, we examined CD154
mRNA expression in T cells that had been stimulated
with plate-bound anti-CD3 with or without IL-4 or IL-
12. Surprisingly, we observed the highest levels of CD154
mRNA expression in naive, unstimulated AND T cells
(Fig. 2 C), even though we could not detect any CD154
protein on the surface of these cells (not depicted). After
anti-CD3 stimulation, CD154 mRNA expression in
AND T cells began to decrease within 6 h and was re-
duced to near background levels by 24 h. CD154 expres-
Figure 1. CD154 expression
can be sustained for up to 72 h
after T cell activation. (A) Puri-
fied naive AND T cells were
stimulated with plate-bound
anti-CD3. Cells were removed
from culture at the times indi-
cated and CD154 expression was
analyzed by flow cytometry.
Open histograms represent con-
trol staining, whereas shaded his-
tograms represent CD154 ex-
pression. (B) Purified naive
AND T cells were cultured with
peptide bearing CH12 cells.
Cells were removed from culture
at the times indicated and CD154 expression on Thy-1  T cells was ana-
lyzed by flow cytometry. Open histograms represent control staining,
whereas shaded histograms represent CD154 expression. Control staining
for CD154 was performed by adding excess unlabeled MR-1 before the
standard staining procedure. The numbers in each panel represent the
percentage of cells staining more brightly than controls. The data shown
are representative of more than three independent experiments. 
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sion then increased slightly at 48 and 72 h after stimula-
tion. The addition of IL-4 resulted in the maintenance of
high levels of CD154 mRNA at 6 h, even though CD154
mRNA expression was dramatically lower at later times,
particularly at 24 and 48 h (Fig. 2 C). In contrast, the ad-
dition of IL-12 maintained CD154 mRNA expression
throughout the course of the experiment (Fig. 2 C). These
data are expressed quantitatively in Fig. 2 D. Together,
these results demonstrate that although the late phase of
CD154 surface expression is negatively regulated by IL-4,
this regulation is only partly mediated by changes in
CD154 mRNA expression.
 
The Second Phase of CD154 Expression Is Differentially
Regulated on Polarized T Cell Subsets. 
 
Because IL-4 and
IL-12 are the predominant cytokines that determine
whether naive T cells develop into Th1 or Th2 effector
cell types (39, 41), we examined whether T cells that had
fully differentiated into Th1 or Th2 effector cells differed
in their kinetics of CD154 expression after reactivation.
We initially examined the expression of CD154 after the
restimulation of day 4 Th1 and Th2 effector cells in a cog-
nate interaction with peptide-bearing CH12 cells. Al-
though CD154 expression was observed on both Th1 and
Th2 effectors 6 h after restimulation, significantly more of
the Th1 cells (40%) compared with the Th2 cells (11%) ex-
pressed CD154. As observed on stimulated naive T cells,
CD154 expression declined by 24 h after stimulation (not
depicted), however, it was impossible to examine CD154
expression at times later than 24 h because most of the re-
stimulated effector T cells had already undergone activa-
tion-induced cell death (not depicted). Therefore, we next
examined the expression of CD154 on restimulated polar-
ized memory T cells, which are not susceptible to activa-
tion induced cell death.
Memory Th1 and Th2 AND T cells were generated by
“parking” day 4 polarized effectors in irradiated, thymecto-
mized recipients (38). After 6 wk, the resulting resting
memory Th1 and Th2 cells were purified from recipient
mice and were restimulated with CH12 cells presenting
PCCF. Unstimulated Th1 and Th2 memory cells did not
express CD154 on their surface (not depicted). However,
as shown in Fig. 3 A, restimulated Th1 memory cells ex-
pressed high levels of CD154 at 6 h, and although CD154
expression declined at later times, it was maintained at sig-
nificant levels for longer than 72 h. Interestingly, the tem-
porary drop in CD154 expression that typically occurs at
24 h after the stimulation of naive AND T cells with CH12
cells and PCCF was not observed with restimulated Th1
memory cells (Fig. 3 A). In contrast to the sustained ex-
pression of CD154 after stimulation of Th1 memory cells,
restimulated Th2 memory cells expressed lower levels of
CD154 at 6 h and expressed barely detectable levels of
CD154 at 24, 48, and 72 h (Fig. 3 A). The differences in
the kinetics of CD154 expression on restimulated Th1 and
Th2 memory cells are summarized graphically in Fig. 3 B.
Overall, the differential expression of CD154 on polarized
effector and memory Th cells is consistent with the changes
in CD154 expression caused by IL-4 and IL-12.
 
The Differential Expression of CD154 on Polarized T Cell
Subsets Is Regulated by the Cytokines Produced by the T
Cells.
 
There were two possible explanations for the dif-
ferences in CD154 expression in Th1 and Th2 memory
Figure 2. Cytokines control the second phase of CD154 expression.
(A) Purified naive AND T cells were stimulated with peptide-bearing
CH12 cells in the presence of the indicated cytokines. Cells were re-
moved from culture at the times indicated and CD154 expression on
Thy-1  T cells was analyzed by flow cytometry. Open histograms repre-
sent control staining, whereas shaded histograms represent CD154 ex-
pression. (B) Purified naive AND T cells were cultured with plate-bound
anti-CD3 in the presence of the indicated cytokines. Cells were removed
from culture at the times indicated and CD154 expression was analyzed
by flow cytometry. Open histograms represent control staining, whereas
shaded histograms represent CD154 expression. (C) RNA was purified
from AND T cells that had been stimulated by plate-bound anti-CD3
alone or with IL-4 or IL-12. 5  g of purified total RNA was separated on
a Northern blot, which was probed with the cDNA for CD154 and with
the cDNA for a mitochondrial enzyme, CHO-B, as a loading control.
(D) The amount of CD154 probe bound to the Northern blot was quan-
titated using a BioRad Molecular Imager FX PhosphorImager. The
quantity shown represents the relative signal within the specific band mi-
nus the signal in an equivalent area adjacent to the specific band. 
697
 
Lee et al.
 
cells. First, it was possible that CD154 expression is intrin-
sically polarized in Th1 and Th2 cells, much like the ex-
pression of IFN-
 
 
 
 and IL-4. Alternatively, differences in
the pattern of CD154 expression observed in Th1 and Th2
cells could be a secondary effect of the polarized produc-
tion of one or more cytokines, such as IL-4, that in turn
regulate CD154 expression. To distinguish between these
possibilities, Th1 memory cells were restimulated with
CH12 cells and PCCF in the presence of either IL-4 or
anti-IFN-
 
 
 
. As shown in Fig. 3 C, the addition of IL-4
dramatically reduced the surface expression of CD154 on
restimulated Th1 memory cells at 24, 48 and 72 h. In con-
trast, the addition of the IFN-
 
 
 
– blocking antibody had no
effect on either the level of CD154 or the percentage of
CD154 positive T cells at any time (Fig. 3 C). The con-
verse experiment was also performed, in which Th2 mem-
ory cells were restimulated with CH12 cells and PCCF in
the presence of IFN-
 
 
 
, IL-12 or anti–IL-4, as shown in
Fig. 3 D. The addition of either IFN-
 
 
 
 or IL-12 did not
restore CD154 expression at later times, suggesting that the
expression of IL-4 by Th2 memory cells, but not in Th1
memory cells, was primarily responsible for the difference
in expression of CD154 on these cell types. Consistent
with this, the addition of IL-4–blocking antibody to cul-
 
tures of stimulated Th2 memory cells partially restored the
second phase of CD154 expression, particularly at 48 h
(Fig. 3 D).
Given that the polarized expression of cytokines by Th1
and Th2 cells is thought to be stabilized by permanent
changes in the chromatin structure of cytokine genes (41),
it was surprising that IL-4 could reverse the extended ex-
pression of CD154 on memory Th1 cells. To ensure that
the Th1 and Th2 memory cells were indeed activated and
remained polarized, we measured the production of IL-2
and IFN-
 
 
 
 by Th1 cells that had been stimulated with or
without IL-4, and we measured the production of IL-2 and
IL-4 by Th2 cells that had been stimulated with or without
IL-12. Although the addition of IL-4 completely blocked
the expression of CD154 at later times on stimulated Th1
memory cells (Fig. 3 C), these cells still made significant
amounts of IFN-
 
 
 
 (Fig. 3 E). Furthermore, Th1 memory
cells stimulated in the presence of IL-4 made levels of IFN-
 
 
 
similar to those made by Th1 memory cells stimulated in
the absence of IL-4 (Fig. 3 E). However, the addition of
IL-4 did consistently reduce the amount of IL-2 produced
by stimulated Th1 memory cells at 6, 24, and 48 h (Fig. 3
E). In the converse experiment, peptide-stimulated Th2
memory cells produced nearly identical levels of IL-4 and
Figure 3. CD154 expression is dif-
ferentially regulated on activated po-
larized Th1 and Th2 memory T cells.
(A) Polarized Th1 and Th2 memory
AND T cells were purified from re-
cipient mice and stimulated with pep-
tide bearing CH12 cells. Cells were
removed from culture at the times in-
dicated and CD154 expression on
Thy-1  T cells was analyzed by flow
cytometry. Open histograms represent
control staining, whereas shaded histo-
grams represent CD154 expression. (B)
The percentage of Th1 and Th2
memory AND T cells that expressed
CD154 at the indicated times in A are
shown graphically. (C) Polarized Th1 memory AND T cells were purified from recipient mice and stimulated with peptide bearing CH12 cells in the
presence of media alone, IL-4, or anti-IFN- . Cells were removed from culture at the times indicated and CD154 expression on Thy-1  T cells was an-
alyzed by flow cytometry. Open histograms represent control staining, whereas shaded histograms represent CD154 expression. (D) Polarized Th2 mem-
ory AND T cells were purified from recipient mice and stimulated with peptide bearing CH12 cells in the presence of media alone, IFN- , IL-12, or
anti–IL-4. Cells were removed from culture at the times indicated and CD154 expression on Thy-1  T cells was analyzed by flow cytometry. Open his-
tograms represent control staining, whereas shaded histograms represent CD154 expression. (E) Supernatants from the experiment in C were collected at
6, 24, and 48 h and assayed for IL-2 and IFN- . (F) Supernatants from the experiment in D were collected at 6, 24, and 48 h and assayed for IL-2 and
IL-4. Data shown are representative of multiple independent experiments. 
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IL-2 as those stimulated in the presence of IL-12 (Fig. 3 F).
Thus, despite the ability of IL-4 to profoundly alter CD154
expression on activated Th1 memory cells, both Th1 and
Th2 memory cells remained polarized when activated in
the presence of opposing cytokines.
To more convincingly demonstrate that IL-4 was di-
rectly responsible for the lowered expression of CD154 at
later times on activated Th2 memory cells, Th2 memory
cells were generated from AND–IL-4KO mice and the ki-
netics of CD154 expression on these cells was compared
with the kinetics of CD154 expression on WT AND Th2
memory cells after activation. When restimulated with
anti-CD3, the IL-4KO Th2 memory cells expressed levels
of CD154 similar to WT Th2 memory cells at 6 h (Fig. 4,
A and B). However, although the expression of CD154
rapidly declined on WT Th2 memory cells after 6 h, the
expression of CD154 on activated IL-4KO Th2 memory
cells remained consistently higher (Fig. 4 A) and was sus-
tained longer (Fig. 4 B). Although the inability to make IL-4
clearly influenced CD154 expression, the typical cytokines
made by restimulated Th2 memory cells, such as IL-5 and
IL-6, were produced in similar quantities from both AND-
WT as well as AND–IL-4KO (not depicted) demonstrating
that the cells were still Th2 cells. These data are consistent
with those in Fig. 3 and suggest that IL-4 is the predomi-
nant cytokine controlling the second phase of CD154 ex-
pression on activated T cells.
 
Sustained CD154 Expression on Activated T Cells Can In-
hibit Antibody Production by CH12 Cells.
 
In previous (20)
studies, we had observed that B cell terminal differentiation
and antibody secretion were specifically blocked by the in-
teraction of B cells with cells that constitutively expressed
CD154 (20). Given these results, we hypothesized that the
sustained CD154 expression observed on T cells stimulated
in the presence of IL-12 could prevent antibody secretion
by B cells in a model of cognate T–B interaction. To test
this, the ability of CH12 cells to differentiate into anti-
body-secreting cells was examined when they were used as
APCs to present PCCF to naive AND T cells in the pres-
ence of IL-4 or IL-12. Since naive T cells do not initially
produce enough cytokines to induce CH12 cell differentia-
tion, LPS was added to the cultures to trigger the differen-
tiation of CH12 cells into IgM-secreting cells. After 72 h of
culture, equivalent numbers of B cells were washed and
recultured for an additional 6 h. Supernatants from the
6-h culture were collected to determine the amount of an-
tibody secreted by the B cells.
As seen in Fig. 5 A, LPS-stimulated CH12 cells secreted
antibody in the absence of T cells (Fig. 5 A, white bars) re-
gardless of the addition of peptide, cytokines or antibodies.
Furthermore, the addition of T cells had no effect on anti-
body secretion in the absence of peptide (not depicted).
However, consistent with our previous report (20), we
found that a cognate encounter between naive T cells and
peptide-bearing CH12 cells could inhibit antibody secre-
tion at 72 h (Fig. 5 A, PCCF black bar). This inhibition
was demonstrated to be CD154 dependent, as the addition
of the CD154-blocking antibody, MR-1, reversed the ef-
fect (Fig. 5 A, PCCF/MR-1 black bar). The differentia-
tion of LPS-activated CH12 cells was similarly inhibited
when the duration of CD154 expression on T cells was
augmented with IL-12 (Fig. 5 A, PCCF/IL-12 black bar).
Again, the block in antibody secretion was shown to be
CD154 dependent using MR-1 (Fig. 5 A, PCCF/IL-12/
MR-1 black bar). However, antibody secretion was not
inhibited when IL-4 was included in the cultures (Fig. 5
A, PCCF/IL-4 black bar), and was unaltered on addition
of MR-1 (Fig. 5 A, PCCF/IL-4/MR-1 black bar). Be-
cause IL-4 does not induce differentiation of CH12 cells
by itself (20, 37) and cannot overcome the CD40-medi-
ated block of antibody secretion even in combination with
LPS (20), IL-4 must allow antibody secretion in this assay
by inhibiting the sustained expression of CD154 on the
activated T cells.
MR-1 is often used to block T cell activation in vivo
(42, 43), presumably by blocking APC activation. How-
ever, because CH12 cells are constitutively activated and
express high levels of costimulatory molecules, MR-1 does
not block T cell activation in our experiments. This is
demonstrated in Fig. 5 B, in which AND T cells that had
been stimulated for 48 h under the conditions of the previ-
ous experiment expressed similarly enhanced levels of the
activation markers CD25, CD44, and CD69 relative to
their resting counterparts. Furthermore, these T cells pro-
duced similar levels of IL-2 at this time under all conditions
tested (not depicted). Therefore, naive AND T cells stimu-
lated with peptide-presenting CH12 cells become equiva-
lently activated, regardless of cytokine or MR-1 addition.
Thus, the primary effect on antibody secretion must be
mediated through changes in the duration of CD154 ex-
pression and not by differential T cell activation.
These results predicted that the ability to inhibit an-
tibody secretion through sustained CD154 expression
would be a property of Th1 memory cells, but not Th2
memory cells. Therefore, cultures were set up containing
either Th1 or Th2 memory AND T cells and CH12 cells
Figure 4. IL-4–deficient memory
Th2 cells can express CD154 with ex-
tended kinetics. (A) Polarized Th2
memory AND T cells were generated
from AND mice on the C57BL/6 back-
ground or from AND mice on the
C57BL/6–IL-4KO background. Mem-
ory T cells were purified from recipients
and were stimulated with plate-bound
anti-CD3. Cells were removed from
culture at the times indicated and
CD154 expression on Thy-1  T cells
was analyzed by flow cytometry. Open
histograms represent control staining,
whereas shaded histograms represent
CD154 expression. (B) The percentage
of T cells staining more brightly than
controls was calculated by electronic
gating at each time. This experiment
was performed twice with similar results. 
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presenting PCCF, with or without exogenous IL-5 to trig-
ger CH12 cell differentiation. After 48 h of culture, equiv-
alent numbers of B cells were washed and recultured to
measure antibody secretion. As predicted, activated Th1
memory cells inhibited CH12 cell differentiation and anti-
body secretion (Fig. 5 C, Th1 PCCF white bar), even
when exogenous IL-5, a potent inducer of CH12 terminal
differentiation, was added to the cultures (Fig. 5 C, Th1
PCCF black bar). Furthermore, this inhibition was CD154
dependent because the addition of MR-1 restored anti-
body secretion to levels seen from CH12 cells stimulated
with IL-5, in the absence of T cells. However, activated
Th2 memory cells were unable to inhibit antibody secre-
tion (Fig. 5 C, Th2 PCCF white or black bars). The ex-
pression of CD154 was monitored in parallel cultures at 6,
24, 48, and 72 h and was found to be similar to that in Fig.
3, in which sustained CD154 expression was observed on
Th1 memory cells and transient CD154 expression was
observed on Th2 memory cells (not depicted). Therefore,
the sustained expression of CD154 after the activation of
either naive T cells or memory Th1 cells, but not memory
Th2 cells, was sufficient to block B cell terminal differenti-
ation and antibody secretion.
An alternative explanation for the lack of IgM secretion
from CH12 cells cultured with Th1 cells was that the T
cells were inducing isotype switching in CH12 cells. How-
ever, we obtained similar results when we performed
ELISAs specific for 
 
 
 
 light chain rather than IgM, suggest-
ing that isotypes other than IgM do not make up any sig-
nificant fraction of the secreted antibody in these experi-
ments (not depicted). Furthermore, we have found little
evidence for isotype switching in the CH12 cell line that
we are using under any conditions (unpublished data).
 
Sustained CD154 Expression on Activated T Cells Can
Inhibit the Terminal Differentiation of Normal Activated B
Cells.
 
Although CH12 is a useful cell line that can be eas-
ily manipulated to dissect the molecular events that occur
in the late stages of B cell differentiation (37, 44), it does
not necessarily reflect the activity of normal B cells. There-
fore, we wished to confirm our observations using acti-
vated normal B cells to present antigen to AND T cells.
Because resting B cells are not efficient APCs, we activated
purified splenic B cells with anti-
 
 
 
 and the cytokine BAFF
for 24 h. We used anti-
 
 
 
 as a surrogate antigen to stimulate
B cell activation and BAFF as a non-T cell–derived sur-
vival/proliferation factor for B cells (45). This combination
was sufficient to induce the expression of both B7.1 and
B7.2 on B cells and to make them efficient APCs (not de-
picted). These activated B cells were then cultured for 72 h
with naive AND T cells in the presence of LPS or the
combination of IL-2, IL-5, and IL-10 to induce antibody
secretion, PCCF to induce T cell activation, and either IL-4
or IL-12 to modulate CD154 expression. The CD154-
blocking antibody, MR-1, was added to parallel cultures to
block CD154–CD40 interactions. As shown in Fig. 6 A,
the AND T cells expressed CD154 within 6 h regardless of
IL-4 or IL-12 addition. However, CD154 expression was
suppressed in the IL-4–stimulated cultures at 24, 48, and
Figure 5. Sustained CD154 expression inhibits antibody secretion by
CH12 cells during a cognate T–B interaction. (A) CH12 cells were cul-
tured alone (white bars) or with naive AND T cells (black bars) in the
presence of the indicated combinations of cytokines, MR-1 and PCCF.
All cultures included LPS to induce the differentiation of CH12 cells. Af-
ter 72 h, cells were removed from culture, counted, and an aliquot of
cells was stained with anti–Thy-1 to determine relative B and T cell
numbers. The remaining cells were washed in PBS and recultured at
equivalent B cell concentrations in fresh media without any additional
stimulation for another 6 h. Antibody secretion was measured in the 6-h
supernatants by ELISA. The data shown are representative of three inde-
pendent experiments. (B) In a parallel experiment, purified naive AND T
cells were cultured with CH12 cells in the presence of the indicated
combinations of PCCF, IL-4, and IL-12 for 48 h with MR-1 (open his-
tograms) or without MR-1 (shaded histograms). Cells were stained with
anti–Thy-1 to identify T cells and with anti-CD25, anti-CD44, or anti-
CD69 to measure the levels of these activation markers. The data shown
are gated on Thy-1  cells. The levels of activation markers on unstimu-
lated naive AND T cells are shown (dotted lines). (C) PCCF-bearing
CH12 cells were cultured alone with AND Th1 memory cells or with
AND Th2 memory cells in the presence or absence of MR-1 as indi-
cated. To induce CH12 differentiation, IL-5 was included in some cul-
tures (black bars), and excluded in others (white bars). After 48 h, cells
were removed from culture, counted, and an aliquot of cells was stained
with anti–Thy-1 to determine relative B and T cell numbers. The re-
maining cells were washed in PBS and recultured at equivalent B cell
concentrations in fresh media for another 6 h. Antibody secretion was
measured in the 6-h supernatants by ELISA. CD154 expression in this
experiment was similar to that in Fig. 3. The data shown are representa-
tive of three independent experiments. 
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72 h, whereas CD154 expression was observed at these
times in the IL-12–stimulated cultures.
To determine whether the modulation of CD154 ex-
pression on T cells by IL-4 or IL-12 controlled the ability
of activated B cells to differentiate into antibody-secreting
cells, we assayed antibody secretion at 72 h. Neither IL-4
nor IL-12 influenced antibody secretion in cultures that did
not contain T cells (not depicted). However, as shown in
Fig. 6 B, activated B cells cultured with AND T cells in the
presence of IL-4 secreted antibody (Fig. 6 B, white bars).
Although B cells stimulated with the combination of IL-2,
IL-5, and IL-10 secreted more antibody than those stimu-
lated with LPS in the IL-4–containing cultures (Fig. 6 B,
white bars), it was important to note that the addition of
MR-1 did not influence antibody secretion in either case.
In contrast, activated B cells cultured with AND T cells in
the presence of IL-12 secreted very little antibody regard-
less of whether the B cells were stimulated with LPS or the
combination of IL-2, IL-5 and IL-10 (Fig. 6 B, black bars).
Furthermore, antibody secretion was substantially increased
in IL-12–treated cultures by the addition of MR-1, dem-
onstrating that CD154 expression was responsible for the
reduction of antibody secretion in cultures containing IL-
12. Although secreted IgG made up only a minor fraction
of total antibody in this experiment (not depicted), similar
results were observed when the secretion of total IgG was
evaluated. Thus, the reduction in IgM secretion by cells
cultured with IL-12 could not be explained by preferential
switching to IgG.
To test whether sustained CD154 expression altered the
antibody-secreting ability of B cells that had been activated
in a more physiological setting, we purified antigen-specific
B cells from mice that had been immunized 7 d previously
with NP-conjugated pigeon cytochrome 
 
c
 
 (NP-PCC).
NP-binding, CD138
 
 
 
 cells (NP-specific, nonplasma cells)
were sorted (Fig. 7 A) and cultured alone or with Th1 or
Th2 memory AND T cells for 72 h in the presence of LPS
and PCCF, with or without MR-1. As shown in Fig. 7 B,
both Th1 and Th2 memory cells were activated by pep-
tide-presenting B cells to express CD154 by 6 h. However,
although Th1 memory cells activated by PPC-presenting
NP-specific B cells maintained CD154 expression at later
times, Th2 memory cells did not (Fig. 7 B). To determine
whether antibody secretion was influenced by CD154 ex-
pression patterns on Th1 or Th2 memory cells, we mea-
sured NP-specific IgG in culture supernatants after 72 h.
NP-specific IgG was produced by the LPS-stimulated B
cells in the absence of T cells, regardless of MR-1 addition
(Fig. 7 C, white bars). Similar levels of IgG were produced
by B cells cultured with Th2 AND memory T cells in the
Figure 6. Sustained CD154 expression inhibits antibody secretion by
activated splenic B cells during a cognate T–B interaction. (A) Purified
splenic B cells were stimulated with rabbit Fab 2 anti-IgM and superna-
tants from BAFF-transfected L cells for 24 h. These activated B cells were
then cultured with PCCF and purified naive AND T cells in the presence
of LPS or a combination of IL-2, IL-5, and IL-10 to stimulate antibody
production by the B cells and either IL-4 or IL-12 to modulate CD154
expression on T cells. MR-1 was included in parallel cultures to block
CD154–CD40 interactions. Cells were removed from culture at the times
indicated and CD154 expression on Thy-1  T cells was analyzed by flow
cytometry. Open histograms represent control staining, whereas shaded
histograms represent CD154 expression. (B) Cells were harvested at 72 h,
washed, and recultured at equivalent B cell concentrations for an addi-
tional 6 h. Secreted antibody was measured by ELISA.
Figure 7. Sustained CD154
expression inhibits antibody se-
cretion by NP-specific germinal
center B cells. (A) B10.BR mice
were immunized with NP-PCC
and NP-OVA and NP-specific
B cells were purified 7 d later by
a combination of positive selec-
tion and cell sorting. The NP-
specific cells were identified by
their ability to bind NP-allophy-
cocyanin and antibody-secret-
ing cells were excluded by the
expression of CD138 (syndecan).
(B) Sorted NP-specific B cells
were cultured with PCCF, LPS,
and either Th1 AND memory T
cells or Th2 AND memory T
cells. MR-1 was included in par-
allel cultures to block CD154–
CD40 interactions. Cells were
removed from culture at the
times indicated and CD154 ex-
pression on Thy-1  T cells was
analyzed by flow cytometry.
Open histograms represent con-
trol staining, whereas shaded his-
tograms represent CD154 ex-
pression. (C) Cells were
harvested at 72 h, washed, and
recultured at equivalent B cell
concentrations for an additional
6 h. Secreted NP-specific anti-
body was measured by ELISA. 
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presence or absence of MR-1. However, we observed a
dramatic drop in IgG production by B cells that had been
cultured with Th1 AND memory T cells. As expected, an-
tibody production in Th1 cultures was restored by the ad-
dition of MR-1 (Fig. 7 C), demonstrating again that the
sustained expression of CD154 leads to the prevention of
antibody secretion by B cells. Unlike the previous experi-
ment, the antibody secreted under these conditions con-
sisted almost entirely of IgG, with nearly undetectable lev-
els of IgM (not depicted). This is most likely due to the fact
that most of the germinal center B cells had already
switched to IgG before they were isolated.
Discussion
CD154 Expression Can Be Sustained for Extended Periods
on Activated CD4  T Cells. The initial studies of CD154
expression on activated T cells concluded that CD154 was
expressed only transiently after activation (46, 47). Thus,
many subsequent studies examined CD154 expression only
at early times after activation, reinforcing the concept that
CD154 was expressed only transiently (23, 30). Contrary to
this prevailing dogma, the results presented here demon-
strate that CD154 expression can easily be sustained on ac-
tivated T cells for at least 72 h. This sustained expression of
CD154 could be observed on either anti-CD3 (without
anti-CD28) or APC/peptide-stimulated T cells (Figs. 1 and
2) and was most easily observed on cells stimulated under
Th1-inducing conditions (Figs. 2 and 3). Moreover, our
results suggest that CD154 expression is not simply sus-
tained, but that there are two discreet phases of CD154 ex-
pression that are regulated by different mechanisms. A dis-
tinction between the first and second phases of CD154
expression is most easily discerned on T cells that have
been stimulated with antigen bearing APCs, as these cells
appear to internalize CD154 at 24 h after stimulation, be-
fore the reappearance of CD154 at 48 h. This is consistent
with previous results demonstrating that CD154 is internal-
ized after contact with its receptor CD40 (25). Thus, stud-
ies that followed the kinetics of CD154 expression for only
24 h would find that CD154 expression peaked within 6–8 h
after activation and dropped to nearly background levels by
24 h. Those studies that did examine CD154 expression at
later times often reported robust CD154 expression, but
concluded that the observed expression was due to a novel
aspect of that experiment, such as the addition of costimu-
lation, cytokines, or the source of T cells (27, 29, 32). Our
results agree with those that reported that CD154 expres-
sion can be sustained under some circumstances, particu-
larly under Th1-inducing conditions.
The Second Phase of CD154 Expression Is Regulated by the
Polarizing Cytokines IL-12 and IL-4. Not surprisingly, the
kinetics of CD154 expression on T cells after activation
was found to be dependent on the activating stimulus, the
presence of cytokines and the differentiation state of the re-
sponding T cells. The first phase of CD154 expression ap-
pears to be induced by TCR engagement alone, which is
consistent with results showing that a more avid TCR sig-
nal increases CD154 expression between 2 and 8 h after ac-
tivation (30), but that neither costimulation nor cytokine
addition had significant effects (30). However, the second
phase of CD154 expression is under more complex con-
trol. IL-4 negatively regulates CD154 expression during
the second phase, whereas the absence of IL-4 allows sus-
tained CD154 expression at these later times. Interestingly,
there is a bimodal distribution of CD154 on T cells acti-
vated for only 6 h (Figs. 1–4), which resolves into a unimo-
dal expression pattern at later times. This raises the possibil-
ity that IL-12 or IL-4 preferentially expand the cells that
were initially either CD154  or CD154 , and that the
subsequent effector populations simply continue to express
CD154 (or not). However, sorting experiments demon-
strated that both initial populations have the ability to ex-
press CD154 at later times (not depicted) and suggested
that cytokine signaling, rather than selective outgrowth,
controls CD154 expression on effector T cells. Consistent
with the idea that IL-4 controls CD154 expression, CD154
is only transiently expressed on activated Th2 memory
cells, whereas its expression is sustained on activated Th1
memory cells that are programmed not to produce any IL-4.
Thus, the second phase of CD154 expression appears to
be regulated according to the Th1–Th2 paradigm. How-
ever, unlike IFN-  production (41), the sustained expres-
sion of CD154 on activated Th1 cells is not a fixed prop-
erty of these cells because the addition of IL-4 can block
extended expression of CD154 on activated Th1 memory
cells, but not the production of IFN- . Therefore, it seems
that extended CD154 expression is a secondary effect of
polarized cytokine production, and that the inability of
Th1 cells to produce IL-4 allows extended CD154 expres-
sion. This is an important observation in two respects. First,
it demonstrates functional IL-4 receptor signaling on polar-
ized Th1 memory cells, even though IL-4 receptor signal-
ing is thought to be impaired in polarized Th1 effectors
(48). Second, it suggests that the ability of Th1 cells to
induce CD40-dependent inflammatory responses can be
tempered by Th2 cytokines, which may have important
therapeutic benefits in diseases where Type 1 cells are
pathogenic (49).
Sustained Expression of CD154 Can Alter T Cell Effector
Functions. CD40 signaling has been implicated in the acti-
vation/differentiation of all APCs, including B cells (31),
macrophages (50, 51) and dendritic cells (52), and there-
fore, plays a central role in almost all immunological pro-
cesses. Thus, it is reasonable to predict that factors affecting
the ability of T cells to express CD154 would have a pro-
found impact on the ability of T cells to influence APC ac-
tivation or differentiation. A major effector function of
CD4  T cells is to provide B cell “help” and, not surpris-
ingly, CD40 signaling is a critical component of T cell–
dependent B cell help as CD40 signaling on B cells is
necessary for Ig isotype-switching (3, 12, 53), affinity mat-
uration (11), and germinal center formation (2, 3, 9). Here,
we show that the ability of Th cells to promote B cell ter-
minal differentiation and antibody secretion is, in part, de-
pendent on their ability to limit the duration of CD154 ex-702 Duration of CD154 Expression Controls CD40 Signaling
pression. Activated Th1 memory cells express CD154 for
longer than 3 d and suppress antibody secretion from acti-
vated B cells during this time. Conversely, activated Th2
memory cells express CD154 for  12 h and allow anti-
body secretion to proceed.
Despite these differences, we believe that Th1 cells are
still capable of providing B cell help and promoting robust
antibody production in vivo. Although there is a persistent
notion that Th1 cells are poor at inducing humoral im-
mune responses, both Th1 and Th2 cells can provide B cell
help in vivo (54). Additionally, our current results clearly
show that Th1 cells have the ability to promote antibody
secretion by B cells, as long as CD40 signaling is checked
(Fig. 7). Furthermore, previous results from several groups
demonstrated that although sustained CD40 signaling
could inhibit antibody secretion by B cells, it maintained B
cell activation and proliferation, and once B cells were re-
moved from the source of CD154 they were capable of se-
creting antibody normally (16, 20). Therefore, it is proba-
bly more accurate to suggest that Th1 and Th2 cells
provide different kinds of B cell help. Interactions with
Th1 cells might favor more extensive B cell proliferation,
switching to isotypes, such as IgG2a, and delayed antibody
secretion due to extended CD40 engagement. On the
other hand, interactions with Th2 cells might favor less B
cell proliferation and more rapid terminal differentiation
and antibody secretion due to a limited CD40 engagement.
Such a situation is easy to visualize in vivo. Antigen-acti-
vated B cells might interact with CD154-expressing Th
cells for several days, thus promoting B cell activation, pro-
liferation and isotype-switching, but preventing B cell ter-
minal differentiation and antibody secretion. Such interac-
tions might occur in germinal centers, which are known to
be dependent on CD40 signaling (9). Subsequently, some
of the activated B may migrate to locations devoid of
CD154-expressing T cells, which would effectively end
CD40 signaling and allow B cell terminal differentiation.
Thus, the ability of sustained CD40 signaling by Th1 cells
to temporarily block antibody secretion does not preclude
an important role for sustained CD40 signaling in facilitat-
ing robust IgG2a antibody responses.
Although Th1 cells can play an important role in hu-
moral immunity, they are most often associated with cell-
mediated immunity. It is intriguing that we find that IL-12
sustains the expression of CD154 on activated T cells (Fig.
2) because it also appears that CD40 signaling can promote
the production of IL-12 and other inflammatory cytokines
by APCs (55–58). In addition, CD40 signaling has been
shown to be an important regulator of the inflammatory
process and the development of Th1 cells (59, 60). Thus, it
is tempting to speculate that signals generated in T cells by
inflammatory cytokines and signals generated in APCs
through CD40 are involved in a positive feedback loop
that generates and maintains an inflammatory type 1 re-
sponse. Consistent with this, CD40 signaling is necessary
for the clearance of microorganisms that require a type 1
response (61–63). However, it is not clear if CD40 signal-
ing is simply necessary to promote the initial polarization of
type 1 responses, or if sustained CD154 expression contrib-
utes to Th1 effector function. Such a contribution may be
the synergism of IFN-  and sustained CD40 signaling lead-
ing to macrophage activation (62). This hypothesis is cur-
rently being investigated.
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